Half-Year 2022 Financial and Clinical Trials Update

Rituxan / Mabthera CER growth -22% Europe -17% Japan -8% Global sales CHFbn CER growth -21% Regional sales 3.6 US 3.0 2.4 1.8 1.2 0.6 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,117m • US: Biosimilar erosion slowing • EU: Biosimilar erosion slowing . Japan: Biosimilar erosion slowing International: Biosimilar erosion slowing CER-Constant Exchange Rates International -19% Roche 177

View entire presentation